GlucoTrack, Inc. (GCTK)
After hours:
| Previous Close | 0.5400 |
| Open | 0.5322 |
| Bid | 0.5645 x 100 |
| Ask | 0.6368 x 100 |
| Day's Range | 0.5300 - 0.6100 |
| 52 Week Range | 0.1330 - 0.9900 |
| Volume | |
| Avg. Volume | 193,172 |
| Market Cap | 16.321M |
| Beta (5Y Monthly) | 0.29 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3800 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireGLUCOTRACK ANNOUNCES ABSTRACTS ACCEPTED FOR POSTER PRESENTATION AT 84TH SCIENTIFIC SESSIONS OF THE AMERICAN DIABETES ASSOCIATION
Continuous blood glucose monitor’s preclinical data and sensor longevity modeling to be presented at major diabetes conference Rutherford, NJ, May 02, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced two abstracts have been accepted for poster presentation at the American Diabetes Association (ADA) 84th Scienti
GuruFocus.comDirector and 10% Owner Drew Sycoff Acquires 182,540 Shares of GlucoTrack Inc (GCTK)
In a recent transaction filed with the SEC, Drew Sycoff, serving as a Director and 10% Owner, has purchased 182,540 shares of GlucoTrack Inc (NASDAQ:GCTK) on April 22, 2024.
- GlobeNewswire
GLUCOTRACK ANNOUNCES CLOSING OF PRIVATE PLACEMENT
Rutherford, NJ, April 22, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that the Company has closed a private placement of securities. The Offering included participation by CEO Paul V. Goode, PhD, as well as other members of the Company’s executive management, Board of Directors, and existing shareholders.
